Here in Berlin, we’re getting desperate for warmth and sunshine, so we moseyed on down to Barcelona to meet Minoryx Therapeutics. The company is developing a treatment for a peroxisomal disorder that leads to lifelong disability, and it’s about to enter Phase II/III.


logo

City: Barcelona, Spain

Founded: 2011

Employees: 11-50

Financial data: €24.4M total raised

Mark Martinelli Minoryx Therapeutics

Mark Martinell, CEO

Mission: Minoryx Therapeutics is focused on a group of rare genetic diseases like X-Linked Adrenoleukodystrophy (X-ALD) and other metabolic disorders that have no available treatment. The company is developing small molecules to address these diseases and sees them all the way through the clinic.

Comment: Minoryx is preparing to launch a Phase II/III trial for their X-linked adrenoleukodystrophy drug, MIN-102, early this year. To support the effort, it just recruited 5 new members to its Scientific Advisory Board from renowned institutions across Europe and the US.

ADVERTISEMENT
Previous post

Will Legos go Bio? The Sustainable Future of 'Greener Toys'

Next post

More News! Pharma hemorrhages money, FDA on Interchangeability

  • Mark Liley

    Fantastic news
    Go science !